Change in the number of shares and votes in BioInvent International AB (publ)

| Source: BioInvent International AB
BioInvent International AB (publ) (OMXS:BINV) today announced that the company’s
total number of shares as per 30 April 2014 amounts to 112,790,050 shares,
corresponding to an equal number of votes. The increase in the number of shares
and votes results from the rights issue of 21,253,662 shares with preferential
right for the company’s shareholders and the directed new share issue of
6,521,739 additional shares, both announced on 24 February 2014.

-- END –

To the editors:

About BioInvent
BioInvent International AB is a research-based pharmaceutical company focused on
discovery and development of innovative antibody-based drugs against cancer. The
Company's pipeline currently includes three product candidates for the treatment
of cancer.

The company has unique expertise in antibody drug development from initial
concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody
library n-CoDeR® are two patented tools that enable identification of relevant
human antibodies and disease targets during the discovery phase. The scope and
strength of this platform is also used to develop antibody-based drugs in
collaboration with partners who finance the development of the new drug, and
provide BioInvent the right to milestone payments and royalties on sales. These
partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and
Mitsubishi Tanabe Pharma. More information is available at

For further information, please contact:

Michael Oredsson
President and CEO
+46 (0)46 286 85 67
+46 (0)707 16 89 30

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

Information disclosed in this press release is provided herein pursuant to the
Swedish Financial Instruments Trading Act. The information was submitted for
publication at 8.40 a.m. CET, on 30 April, 2014.